Company profile · Sponsor
BeiGene
BeiGene Ireland Ltd
- Pipeline
- 4
- Drugs
- 0
- Patents
- 0
Quick answer
BeiGene (E6C2B65) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 4 pipeline programs, 0 drugs, and 0 patents to this profile..
Company facts
Pipeline (4)
Search pipeline →-
normal saline solution for infusion, Ociperlimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Tislelizumab, Ociperlimab
BeiGene
Locally advanced, unresectable, or metastatic non small cell lung cancer
1 trial -
OBINUTUZUMAB, Zanubrutinib
BeiGene
Relapsed/Refractory Follicular Lymphoma
1 trial -
A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB 21447 in Patients With Mature B Cell Malignancies
BeiGene
mature B-Cell malignancies
1 trial -
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors
BeiGene
Advanced or metastatic solid tumors
1 trial
Frequently asked questions
What is BeiGene?
BeiGene (E6C2B65) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 4 pipeline programs, 0 drugs, and 0 patents to this profile..
What pipeline programs does BeiGene sponsor?
We track 4 ClinicalTrials.gov-linked programs for BeiGene, including normal saline solution for infusion, Ociperlimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Tislelizumab, Ociperlimab and 3 more. Open each program for phase, modality, NCT IDs, and indication details.
Where does BeiGene company data come from?
Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.